Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells $148,090.62 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 4,938 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $29.99, for a total value of $148,090.62. Following the completion of the sale, the chief financial officer owned 264,117 shares of the company’s stock, valued at $7,920,868.83. This represents a 1.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.09, for a total value of $1,943,389.47.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The stock was sold at an average price of $34.03, for a total transaction of $619,243.91.

Hims & Hers Health Trading Up 5.7%

Shares of Hims & Hers Health stock opened at $33.67 on Friday. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $65.30. The firm has a market capitalization of $7.86 billion, a PE ratio of -53.44 and a beta of 2.40. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The company’s fifty day moving average price is $32.37 and its two-hundred day moving average price is $26.14.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health’s revenue was up 38.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.17 earnings per share. On average, analysts expect that Hims & Hers Health, Inc. will post -0.14 EPS for the current year.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Analysts and investors see continued expansion opportunities in branded GLP-1 weight-loss products, testosterone, peptides, international markets and AI-driven patient support. These initiatives could strengthen revenue growth and improve operating efficiency over time. What is driving HIMS stock’s rally
• Positive Sentiment: Barclays maintained an “overweight” rating, indicating a favorable long-term view even after reducing its price target from $39 to $35. The revised target remains above the referenced trading level. Barclays price-target update
• Neutral Sentiment: Recent insider sales by CFO Oluyemi Okupe and other executives were made under pre-arranged Rule 10b5-1 plans. While the transactions may create a modest overhang, the insiders continued to hold sizable positions, reducing the signal that management confidence has materially weakened. HIMS insider sales
• Neutral Sentiment: Analyst views remain divided. Needham raised its price target to $42 and kept a Buy rating, while the broader consensus remains Hold, reflecting strong revenue growth but uncertainty around margins and the GLP-1 strategy.
• Negative Sentiment: Three law firms announced investigations into potential securities-law violations. These announcements are investor outreach notices—not findings of wrongdoing—but they add legal, compliance and reputational risk amid scrutiny of privacy practices, billing and subscription cancellations. Kaplan Fox investigation
• Negative Sentiment: The latest quarterly results showed revenue of $753.2 million, up 38.2% year over year and above expectations, but the company reported a $0.37-per-share loss versus the expected $0.05 loss. Persistent losses and weak profitability could limit further upside unless margins improve.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HIMS. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. TD Cowen upped their price target on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a research note on Tuesday, May 12th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and a consensus price target of $32.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Versant Capital Management Inc increased its holdings in Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after purchasing an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares during the last quarter. Binnacle Investments Inc acquired a new position in Hims & Hers Health in the third quarter worth $28,000. Bogart Wealth LLC boosted its stake in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares in the last quarter. Finally, Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health during the first quarter worth $30,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.